Retatrutide 4 mg is an investigational metabolic peptide attracting significant attention in obesity and weight‑management research. Unlike earlier therapies, Retatrutide acts as a triple receptor agonist, targeting GLP‑1, GIP, and glucagon receptors simultaneously. This multi‑pathway approach is designed to influence appetite regulation, glucose control, energy expenditure, and fat m... https://filozofija.edu.rs/o-bolu-prof-dr-damir-smiljanic/#comment-251615